Regulatory Contact
At Sensory Cloud

Loucks’ experience at Sensory Cloud included contact from the FDA along with the Federal Trade Commission earlier in 2022 concerning unsupported COVID-19 claims.

A joint warning letter submitted in April stated that the agencies’ inspections of Sensory Cloud’s website found claims touting its FEND branded spray for COVID-19 prevention. (Also see "Michigan Firm’s Nasal Spray Neither A COVID-19 Treatment Nor For Nasal Use" - HBW Insight, 13 April, 2022.)

The spray, intended to be administered close but not in the nose to provide an inhale of a formulation of with water, calcium and sodium, “should make your own nose and throat more resistant to contracting COVID-19 … by turning your throat into a sticky fly trap for the virus to keep it out of your lungs,” according to a claim noted in the warning.

The online claims also stated that a “Harvard study demonstrates it may have a protective effect against airborne viruses like COVID-19 – similar to wearing a cotton mask,” and with two puffs, “you reduce your chance of exhaling COVID-19-filled droplets by 99% for six hours,” the warning stated.

US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief

More from Rx-to-OTC Switch

More from Health